Abstract
Chronic obstructive pulmonary disease (COPD) is defined by fixed airflow limitation associated with an abnormal pulmonary and systemic inflammatory response of the lungs to cigarette smoke.
The systemic inflammation induced by smoking may also cause chronic heart failure, metabolic syndrome and other chronic diseases, which may contribute to the clinical manifestations and natural history of COPD. Thus COPD can no longer be considered a disease only of the lungs, as it is often associated with a wide variety of systemic consequences.
A better understanding of the origin and consequences of systemic inflammation, and of potential therapies, will most likely lead to better care of patients with COPD. Medical textbooks and clinical guidelines still largely ignore the fact that COPD seldom occurs in isolation.
As the diagnosis and assessment of severity of COPD may be greatly affected by the presence of comorbid conditions, the current authors believe that lung function measurement, noninvasive assessment of cardiovascular and metabolic functions, and circulating inflammatory markers (e.g. C-reactive protein) might help to better characterise these patients. Similarly, preventive and therapeutic interventions should address the patient in their complexity.
Ageing is commonly characterised as a progressive, generalised impairment of function resulting in an increasing vulnerability to environmental challenge and a growing risk of disease. Ageing is highly complex, involving multiple mechanisms at different levels. Current theoretical understanding suggests that cells tend to accumulate damage as they age. Such damage is intrinsically random in nature, but its rate of accumulation is regulated by genetic mechanisms for maintenance and repair. As cell defects accumulate, the effects on the body as a whole are eventually revealed as age-related frailty, disability and disease 1, 2.
Therefore, ageing of the population increases the prevalence of chronic diseases, which represent a huge proportion of human illness. They include cardiovascular disease (30% of projected total worldwide deaths in 2005), cancer (13%), diabetes (2%) and chronic respiratory diseases (7%), mainly chronic obstructive pulmonary disease (COPD) 3.
COPD is a disease state characterised by poorly reversible airflow limitation that is usually progressive and associated with an abnormal inflammatory response of the lungs to noxious particles or gases, particularly cigarette smoke 4. COPD should be considered in any smoker aged >40 yrs with symptoms of cough, sputum production or dyspnoea, and spirometry should be used to evaluate the degree of airflow limitation 4. However, because there is increasing evidence that COPD is a more complex systemic disease than an airway and lung disease, a comprehensive approach including imaging 5, exercise tolerance and body mass index 6 may be required for an earlier diagnosis and better assessment of the disease.
Cigarette smoking is the major risk factor of COPD and is also one of the major risk factors of all chronic diseases and cancer 7, 8. Cigarette smoke causes lung and systemic inflammation, systemic oxidative stress, marked changes of vasomotor and endothelial function and enhanced circulating concentrations of several pro-coagulant factors 9–11. The systemic effects of smoking may significantly contribute not only to respiratory abnormalities, symptoms and functional impairment (e.g. exercise intolerance) associated with COPD 12–15 but also to its chronic comorbidities 12, 16–19. In particular, cachexia 20, skeletal muscle abnormalities 15, 21, 22, hypertension 23, 24, diabetes 25, coronary artery disease 26–28, heart failure 29, pulmonary infections 30–34, cancer 35, 36 and pulmonary vascular disease 37 are the most common comorbidities responsible for the clinical manifestations and natural history of COPD 17, 18. In addition to smoking, the other major risk factor for cardiovascular and other chronic comorbid conditions is obesity 38, 39. Although obesity by itself may profoundly affect lung function 40, its relationship with COPD has been poorly investigated and is still unclear 41. Smoking and obesity are the major risk factors for the complex chronic comorbidities seen throughout the world 42–44. Obese individuals who smoke have a markedly reduced life expectancy 38, 45. The two risk factors may interact synergistically, since both obesity and smoking are associated with insulin resistance, oxidative stress and increased concentrations of various (adipo)cytokines and inflammatory markers, all of which ultimately lead to endothelial dysfunction and cardiovascular diseases 46.
Comorbidities markedly affect health outcomes in COPD 16; in fact, patients with COPD mainly die of nonrespiratory diseases 47–50, such as cardiovascular diseases (∼25%), cancer (mainly lung cancer, 20–33%) and other causes (30%). Respiratory diseases, mainly respiratory failure due to COPD exacerbations, account for 4–35% of deaths, primarily in patients with severe COPD. The wide range of deaths attributable to respiratory diseases may be due to: different criteria used in different populations; the severity of COPD in the population examined 48, 50, 51; or to under-reporting of respiratory conditions on the death certificate 51, 52.
Considering that the pharmacological treatment of COPD to date is primarily symptomatic, a more comprehensive approach to comorbidities may provide an opportunity to modify the natural history of patients with COPD and to identify novel targets for treatment. This is particularly relevant for those conditions that appear more preventable and treatable than COPD, such as cardiovascular and metabolic disorders.
COMPLEX CHRONIC COMORBIDITIES
Chronic diseases, including cardiovascular disease, cancer, chronic respiratory diseases and metabolic syndrome (hypertension, diabetes, dyslipidaemia) 3, 43, are increasing in the developed countries and result in a substantial economic and social burden 3, 42, 43. The cost of individual chronic diseases increases exponentially in patients with two or more comorbid chronic diseases 53; almost half of all elderly people (≥65 yrs) have at least three chronic medical conditions, and one fifth have five or more 54. Patients with two or more chronic diseases account for only 26% of the population but for >50% of the overall costs 53.
The most frequent chronic diseases often develop together 13, 16, 24, 27, 48, 54–59. COPD is associated with chronic heart failure (CHF) in ≥20% of patients 29, 60; there is overwhelming evidence from large-scale epidemiological studies demonstrating that impaired forced expiratory volume in one second is a powerful marker of morbidity and mortality 61 and, particularly, of cardiovascular mortality 62. Interestingly, increased arterial stiffness is also related to the severity of airflow obstruction and may be a factor in the excess risk for cardiovascular disease in COPD 63. Patients with severe COPD have elevated circulating levels of C-reactive protein (CRP) 64. A working hypothesis to account for the high prevalence of left ventricular systolic dysfunction in patients with COPD is that low-grade systemic inflammation accelerates progression of coronary atherosclerosis, which ultimately results in ischemic cardiomyopathy. Such a hypothesis fits the clinical observation of a high incidence of left ventricular wall motion abnormalities noted in patients with COPD and left ventricular dysfunction 64.
Metabolic syndrome is a complex disorder and an emerging clinical challenge, recognised clinically by the findings of abdominal obesity, elevated triglycerides, atherogenic dyslipidaemia, elevated blood pressure, high blood glucose and/or insulin resistance 65. Metabolic syndrome is also associated with a pro-thrombotic state and a pro-inflammatory state. Central pathophysiological features of metabolic syndrome include: 1) insulin resistance; 2) atherogenic dyslipidaemia; 3) arterial hypertension, which occurs frequently in individuals with insulin resistance; 4) a pro-inflammatory state, with increases in acute-phase reactants (e.g. CRP); and 5) a pro-thrombotic state, with increases in plasminogen activator inhibitor and fibrinogen 65. Patients with COPD often have one or more component of the metabolic syndrome 66 and osteoporosis (≤70% of patients) which are at least, in part, independent of treatment with steroids and/or decreased physical activity 63, 67. Even when a specific single chronic comorbidity cannot be diagnosed according to the current criteria, COPD is often associated with a marker of chronic diseases, e.g. decreased tolerance to glucose, hypertension or decreased bone density 63, 68.
Type 2 diabetes is associated with hypertension in >70% of patients, and with cardiovascular diseases and obesity in >80% 69. Diabetes is independently associated with reduced lung function 70, 71, which, together with obesity, may further worsen the severity of COPD 41.
UNDERLYING MECHANISMS AND CONSEQUENCES FOR TREATMENT OF COMPLEX CHRONIC COMORBIDITIES
COPD can no longer be considered a disease only of the lungs 17, 18, 72. It is associated with a wide variety of systemic consequences, most notably systemic inflammation (fig. 1⇓). A better understanding of its origin, consequences and potential therapy will most likely prove to be of great relevance and lead to better care of patients with COPD. The origin of systemic inflammation in COPD is unresolved, although several potential mechanisms have been proposed 12.
Fig. 1— The central role of inflammation in comorbidity is associated with chronic obstructive pulmonary disease (COPD). Inflammation appears to play a central role in the pathogenesis of COPD and other conditions that are increasingly being recognised as systemic inflammatory diseases. As part of the chronic inflammatory process, tumour necrosis factor (TNF)-α receptor polymorphisms are associated with increased severity of disease, possibly due to enhanced TNF-α effects. Also, C-reactive protein (CRP) levels can be increased directly by TNF-α and other cytokines. Elevated CRP and fibrinogen may be crucial in the pathogenesis of cardiovascular disease. Reactive oxygen species released as a result of COPD may enhance the likelihood of a patient developing cardiovascular disease, diabetes and osteoporosis. IL: interleukin; ?: unknown; +ve: positive.
Since smoking remains the major risk factor for the development of COPD and of the associated systemic inflammation 72, the study of the effects of smoking represents the best model for unravelling the underlying mechanisms of COPD and the consequences of systemic inflammation induced by smoking. In fact, cigarette smoke may cause systemic inflammation irrespective of COPD 73, and systemic inflammation in smokers may contribute significantly to the development of cardiovascular diseases, particularly atherosclerosis 74.
Smoking and acute exacerbations of COPD have a marked influence on redox status 75 by increasing levels of lipid peroxidation products and other markers 76. The increase in oxidative stress results in the inactivation of antiproteases, airspace epithelial damage, mucus hypersecretion, increased influx of neutrophils into lung tissue and the expression of pro-inflammatory mediators 77, 78. Inflammatory cells are also increased in peripheral blood, including neutrophils and lymphocytes 79. Furthermore, patients with COPD have increased numbers of neutrophils in the lungs, increased activation of neutrophils in peripheral blood and an increase in tumour necrosis factor (TNF)-α and soluble TNF receptor. Activated T-cells in emphysematous lungs predominantly express a T-helper cell type-1 phenotype and control the release of matrix metalloproteases via chemokines. Recent evidence, obtained through ex vivo experiments with T-cells from COPD patients, suggests that exposure to cigarette smoke induces secretion of proteolytic enzymes from cells of the innate immune system, which in turn liberate lung elastin fragments 80. In susceptible individuals, T- and B-cell-mediated immunity against elastin is initiated. Elastin is also abundant in tissues other than the lung, especially in arteries, arterioles and the skin; its fragments are chemotactic and cause pathology in mouse models of emphysema. These novel findings of anti-elastin autoimmunity in emphysema, together with earlier observations 81–84, suggest a broader, systemic autoimmune process involving the major elastin-bearing organs, such as the (coronary) vasculature and the skin.
To understand the relationship between pulmonary inflammation and systemic disease, common inflammatory pathways have been proposed 19. It is unclear why some patients with COPD have higher baseline concentrations of circulating inflammatory markers 85; whether this systemic inflammation is a primary or secondary phenomenon is a matter of debate. Some patients with COPD who exhibit increased resting energy expenditure and decreased fat-free mass have marked elevation of CRP and lipopolysaccharide-binding protein 86. Systemic inflammation may lead to a lack of response to nutritional supplementation 87, further contributing to the development of cachexia.
Systemic inflammation may also explain why patients with COPD have an increased risk of developing type 2 diabetes 88. Some aspects of inflammation can predict the development of diabetes and glucose disorders 89, 90, while fibrinogen, circulating white blood cell count and lower serum albumin predict the development of type 2 diabetes 89. Furthermore, patients with noninsulin-dependent diabetes mellitus have increased circulating levels of TNF-α, interleukin (IL)-6 and CRP 91, which are also risk factors for cardiovascular events in males and females 92, 93. Diabetes is independently associated with reduced lung function, which together with obesity could further worsen the severity of COPD 41. The complex interaction between smoking and obesity in the development of chronic comorbidities has been recently reviewed (fig. 2⇓) 46.
Fig. 2— Schematic representation of how smoking might add to several mechanisms linking obesity to cardiovascular disease. Red arrows indicate an effect of smoking. HDL: high-density lipoprotein; TNF: tumour necrosis factor; ICAM: intercellular adhesion molecule; ROS: reactive oxygen species; IL: interleukin; CRP: C-reactive protein. Reproduced with permission from 46.
Patients with COPD have an increased risk of developing osteoporosis even in the absence of steroid use; vertebral fractures are present in ≤50% of steroid-naïve males with COPD 94. Post-menopausal osteoporosis is related to high serum levels of TNF-α and IL-6 95, and osteopenia found in COPD is also associated with an increase in circulating TNF-α 96. Increased levels of TNF-α (and IL-1) stimulate the differentiation of macrophages into osteoclasts via mesenchymal cells releasing receptor activator of nuclear factor-κB ligand, a member of the TNF-α superfamily 97.
The development of inflammatory processes associated with COPD is commonly believed to be initiated and maintained in the lung (parenchyma) 98 and to affect peripheral organs as the disease progresses. This concept is not proven and is probably rather naïvely related to the fact that the major risk factors for COPD enter the body by inhalation. To date, the limited data published on the contribution of the systemic circulation to the priming and activation of inflammatory cells in their transit through the pulmonary circulation 99, 100 have been negative, because the concentrations of inflammatory markers in induced sputum (presumably reflecting local inflammation) and plasma (reflecting systemic inflammation) in patients with moderate COPD are not correlated.
Alternatively, some of the nonpulmonary manifestations of COPD may occur early in the course of the disease and affect pulmonary inflammation. For example, inhibition of vascular endothelial growth factor (VEGF) receptors causes lung cell apoptosis and emphysema 101, 102. Furthermore, endothelial cell death and decreased expression of VEGF and the VEGF receptor KDR/FLK-1 occur in patients with smoking-induced emphysema 103. In summary, systemic oxidative stress 75 and the increased levels of pro-inflammatory cytokines could contribute to the pathogenesis of lung damage in COPD early in the course of the disease.
Tissue hypoxia is another mechanism that can contribute to systemic inflammation in COPD. In a recent clinical study 104 it was shown that TNF-α and receptor levels were significantly higher in patients with COPD, but were significantly correlated with the severity of arterial hypoxaemia. These results suggest that arterial hypoxaemia in COPD is associated with activation of the TNF-α system in vivo. If confirmed, this might indeed change the whole view on long-term oxygen therapy. Prolonged survival in patients receiving domiciliary oxygen therapy, as described many years ago 105, 106, might be attributable to an effect on systemic inflammation. This hypothesis could be tested in randomised trials.
Skeletal muscle itself can contribute to systemic inflammation. In particular, this has been demonstrated in patients with COPD during exercise 107, 108. Physical exercise specifically increases plasma TNF-α levels in COPD 109. TNF-α has a variety of effects that could lead to muscle wasting 110. TNF-α effects are mediated by the transcription factor nuclear factor (NF)-κB, which is normally inactive but can be activated by inflammatory cytokines such as TNF-α 96. Different mechanisms by which TNF-α could induce muscle loss have been described previously, including direct stimulation of protein loss, apoptosis of muscle cells and oxidative stress-induced alteration in TNF-α/NF-κB signalling 111. Inflammation and oxidative stress, characteristic of COPD 112, have synergistic effects on muscle breakdown 113.
Under conditions of nutritional imbalance, resting energy requirements are normally reduced 114. This is in contrast to the increased resting energy expenditure that is characteristic of some patients with COPD; the discrepancy is believed to be linked to systemic inflammation 86, 115. Increased oxygen consumption by respiratory muscles seems an incomplete explanation on its own 100, and as nutritional intake in stable disease is, on the whole, sufficient, generally accelerated loss of skeletal muscle in the context of a chronic inflammatory response is the most likely explanation 116. This loss of muscle is not specific to COPD but is generally found in states of cachexia with enhanced protein degradation 117 and poor responsiveness to nutritional interventions 118, 119; it also displays similarities to CHF, renal failure, AIDS and cancer.
Finally, bone marrow is an obvious site of production of systemic inflammation, although knowledge of its role in patients with COPD is sparse. Smoking causes leukocytosis with increased numbers of band cells, a higher content of myeloperoxidase and enhanced surface expression of l-selectin 73. Furthermore, these sequestrated polymorphonuclear leukocytes can be found in lung microvessels 120, supporting the concept that the bone marrow may directly contribute to smoking-induced lung inflammation.
MANAGEMENT OF COPD AS A COMPLEX DISEASE
Although textbooks 121 and guidelines have increasingly recognised the frequency and importance of comorbidities, particularly in the elderly, the fact that chronic diseases seldom occur in isolation is still largely ignore 4, 122, 123. Thus, clinicians treating chronic diseases lack definitions and a vocabulary to describe a syndrome that reflects real-life bedside medicine, not the medicines that have been taught 121. Recently, Fabbri and Rabe 124 suggested adding the term “chronic systemic inflammatory syndrome” to the diagnosis of COPD to reflect the complexity of the problem.
The diagnosis and assessment of severity of COPD may be greatly affected by the presence of a comorbid condition; therefore, lung function measurement, noninvasive assessment of left ventricular function (e.g. echocardiography and brain natriuretic peptide) and/or glycaemia, such as CRP serum levels, should be performed in these patients.
Considerations almost identical to those mentioned previously can obviously be applied to preventive and therapeutic interventions. Smoking prevention and cessation, weight control and diet, and exercise and rehabilitation all have the potential to beneficially affect all components of chronic disease.
Pharmacological treatment is more complex, as drugs are usually developed for single diseases or organs. However, glucose control with insulin or oral antidiabetic agents not only controls diabetes but also prevents systemic effects and comorbidities 123. Likewise, antihypertensive agents not only help control blood pressure but are also associated with dramatic prevention of coronary and cerebrovascular disease, with marked reduction of mortality 125. More recently, these agents have been found to have unexpected beneficial effects on COPD. Statins, which are used primarily as lipid-lowering agents in the treatment of metabolic syndrome, have potent anti-inflammatory properties that might positively affect comorbidities of metabolic syndrome, e.g. COPD, CHF and vascular diseases 126–128. However, on the negative side, β-blockers, which are considered to be life-saving drugs in CHF, might have some risks in COPD patients who have an asthmatic component 129. Furthermore, systemic steroids, which are required to treat COPD exacerbations 130, might negatively affect glucose control and cause osteoporosis and hypertension 131. Even drugs specifically developed and used to treat respiratory diseases, such as inhaled bronchodilators and steroids, may have significant beneficial effects on cardiovascular diseases 132, 133.
SINGLE-DISEASE VERSUS PATIENT-ORIENTED GUIDELINES FOR CHRONIC DISEASES
Clinical practice guidelines are being increasingly used as performance indicators, and have been shown to substantially improve the quality of clinical care. However, most guidelines ignore the fact that the majority of individuals with a chronic disease have one or more comorbidities.
COPD, CHF, peripheral artery disease, diabetes or nonlife-threatening cancer can have a major impact on individuals with a chronic disease, particularly the elderly 14. Therefore, it is evident that clinical practice guidelines, designed largely by specialty-dominated committees for managing single diseases, provide clinicians with little guidance in caring for patients with multiple chronic diseases. This lack of guidance frequently results in polypharmacia in these patients.
It is not only clinicians who will have to change their approach to treating chronic diseases; it is also the healthcare system in general that must rise to this major challenge.
Statement of interest
The study was supported by the Associazione per la Ricerca e la Cura dell'Asma (Padua, Italy) and the Consorzio Ferrara Ricerche, Associazione per lo Studio de tumouri e delle Malattie Polmonari.
Acknowledgments
The authors would like to thank M. McKenney (Menominee, MI, USA) for scientific assistance with the manuscript, and E. Veratelli (University of Modena and Reggio Emilia, Modena, Italy) for scientific secretarial assistance.
Footnotes
-
Previous articles in this series: No. 1: Viegi G, Pistelli F, Sherrill DL, Maio S, Baldacci S, Carrozzi L. Definition, epidemiology and natural history of COPD. Eur Respir J 2007; 30: 993–1013.
- Received August 31, 2007.
- Accepted September 11, 2007.
References
- ↵
Hadley EC, Lakatta EG, Morrison-Bogorad M, Warner HR, Hodes RJ. The future of aging therapies. Cell 2005;120:557–567.
- ↵
Kirkwood TB. Understanding the odd science of aging. Cell 2005;120:437–447.
- ↵
Horton R. The neglected epidemic of chronic disease. Lancet 2005;366:1514
- ↵
Rabe KF, Hurd S, Anzueto A, et al. Global Strategy for the diagnosis, management, and prevention of COPD: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532–555.
- ↵
Omori H, Nakashima R, Otsuka N, et al. Emphysema detected by lung cancer screening with low-dose spiral CT: prevalence, and correlation with smoking habits and pulmonary function in Japanese male subjects. Respirology 2006;11:205–210.
- ↵
Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005–1012.
- ↵
Ezzati M, Lopez AD. Estimates of global mortality attributable to smoking in 2000. Lancet 2003;362:847–852.
- ↵
Mannino DM, Davis KJ. Lung function decline and outcomes in an elderly population. Thorax 2006;61:472–477.
- ↵
MacCallum PK. Markers of hemostasis and systemic inflammation in heart disease and atherosclerosis in smokers. Proc Am Thorac Soc 2005;2:34–43.
-
MacNee W. Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2:50–60.
- ↵
van Eeden SF, Yeung A, Quinlam K, Hogg JC. Systemic response to ambient particulate matter: relevance to chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2:61–67.
- ↵
Agusti A. Thomas A. Neff lecture. Chronic obstructive pulmonary disease: a systemic disease. Proc Am Thorac Soc 2006;3:478–481.
- ↵
Kriegsman DM, Deeg DJ, Stalman WA. Comorbidity of somatic chronic diseases and decline in physical functioning: the Longitudinal Aging Study Amsterdam. J Clin Epidemiol 2004;57:55–65.
- ↵
Di Fazio I, Franzoni S, Frisoni GB, et al. Predictive role of single diseases and their combination on recovery of balance and gait in disabled elderly patients. J Am Med Dir Assoc 2006;7:208–211.
- ↵
Balasubramanian VP, Varkey B. Chronic obstructive pulmonary disease: effects beyond the lungs. Curr Opin Pulm Med 2006;12:106–112.
- ↵
Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J 2006;28:1245–1257.
- ↵
Fabbri LM, Ferrari R. Chronic disease in the elderly: back to the future of internal medicine. Breathe 2006;3:40–49.
- ↵
- ↵
Sevenoaks MJ, Stockley RA. Chronic obstructive pulmonary disease, inflammation and co-morbidity–a common inflammatory phenotype?. Respir Res 2006;7:70
- ↵
Morley JE, Thomas DR, Wilson MM. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 2006;83:735–743.
- ↵
Maltais F. Skeletal muscles in chronic airflow obstruction: why bother?. Am J Respir Crit Care Med 2003;168:916–917.
- ↵
Orozco-Levi M. Structure and function of the respiratory muscles in patients with chronic obstructive pulmonary disease: impairment or adaptation?. Eur Respir J 2003;22: Suppl. 46 41s–51s.
- ↵
Taichman DB, Mandel J. Epidemiology of pulmonary arterial hypertension. Clin Chest Med 2007;28 1–22:vii
- ↵
Wang PS, Avorn J, Brookhart MA, et al. Effects of noncardiovascular comorbidities on antihypertensive use in elderly hypertensives. Hypertension 2005;46:273–279.
- ↵
Blacher J, Safar ME. Large-artery stiffness, hypertension and cardiovascular risk in older patients. Nat Clin Pract Cardiovasc Med 2005;2:450–455.
- ↵
Sidney S, Sorel M, Quesenberry CP Jr, DeLuise C, Lanes S, Eisner MD. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005;128:2068–2075.
- ↵
Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 2005;128:2099–2107.
- ↵
Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005;2:8–11.
- ↵
Rutten FH, Moons KG, Cramer MJ, et al. Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study. BMJ 2005;331:1379
- ↵
Veeramachaneni SB, Sethi S. Pathogenesis of bacterial exacerbations of COPD. COPD 2006;3:109–115.
-
Hogg JC. Infection and COPD. Exp Lung Res 2005;31: Suppl. 1 72–73.
-
Mallia P, Johnston SL. How viral infections cause exacerbation of airway diseases. Chest 2006;130:1203–1210.
-
Almirall J, Bolíbar I, Balanzó X, González CA. Risk factors for community-acquired pneumonia in adults: a population-based case–control study. Eur Respir J 1999;13:349–355.
- ↵
Farr BM, Woodhead MA, Macfarlane JT, et al. Risk factors for community-acquired pneumonia diagnosed by general practitioners in the community. Respir Med 2000;94:422–427.
- ↵
Brody JS, Spira A. State of the art. Chronic obstructive pulmonary disease, inflammation, and lung cancer. Proc Am Thorac Soc 2006;3:535–537.
- ↵
Ben-Zaken Cohen S, Pare PD, Man SF, Sin DD. The growing burden of chronic obstructive pulmonary disease and lung cancer in women: examining sex differences in cigarette smoke metabolism. Am J Respir Crit Care Med 2007;176:113–120.
- ↵
Mal H. Prevalence and diagnosis of severe pulmonary hypertension in patients with chronic obstructive pulmonary disease. Curr Opin Pulm Med 2007;13:114–119.
- ↵
Peeters A, Barendregt JJ, Willekens F, Mackenbach JP, Al Mamun A, Bonneux L. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med 2003;138:24–32.
- ↵
Stevens J, Cai J, Evenson KR, Thomas R. Fitness and fatness as predictors of mortality from all causes and from cardiovascular disease in men and women in the lipid research clinics study. Am J Epidemiol 2002;156:832–841.
- ↵
Parameswaran K, Todd DC, Soth M. Altered respiratory physiology in obesity. Can Respir J 2006;13:203–210.
- ↵
Poulain M, Doucet M, Major GC, et al. The effect of obesity on chronic respiratory diseases: pathophysiology and therapeutic strategies. CMAJ 2006;174:1293–1299.
- ↵
Epping-Jordan JE, Galea G, Tukuitonga C, Beaglehole R. Preventing chronic diseases: taking stepwise action. Lancet 2005;366:1667–1671.
- ↵
Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006;367:1747–1757.
- ↵
Strong K, Mathers C, Epping-Jordan J, Beaglehole R. Preventing chronic disease: a priority for global health. Int J Epidemiol 2006;35:492–494.
- ↵
Huttunen R, Laine J, Lumio J, Vuento R, Syrjanen J. Obesity and smoking are factors associated with poor prognosis in patients with bacteraemia. BMC Infect Dis 2007;7:13
- ↵
Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006;444:875–880.
- ↵
Hansell AL, Walk JA, Soriano JB. What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. Eur Respir J 2003;22:809–814.
- ↵
Mannino DM, Watt G, Hole D, et al. The natural history of chronic obstructive pulmonary disease. Eur Respir J 2006;27:627–643.
-
Mannino DM, Doherty DE, Sonia Buist A. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir Med 2006;100:115–122.
- ↵
McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 2007;62:411–415.
- ↵
Jensen HH, Godtfredsen NS, Lange P, Vestbo J. Potential misclassification of causes of death from COPD. Eur Respir J 2006;28:781–785.
- ↵
Goldacre MJ, Duncan M, Cook-Mozaffari P, Griffith M. Mortality rates for common respiratory diseases in an English population 1979–1998: artefact and substantive trends. J Public Health (Oxf) 2004;26:8–12.
- ↵
Charlson M, Charlson RE, Briggs W, Hollenberg J. Can disease management target patients most likely to generate high costs? The impact of comorbidity. J Gen Intern Med 2007;22:464–469.
- ↵
Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 2005;294:716–724.
-
De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease and prevention in clinical practice. Atherosclerosis 2003;171:145–155.
-
Schraeder C, Dworak D, Stoll JF, Kucera C, Waldschmidt V, Dworak MP. Managing elders with comorbidities. J Ambul Care Manage 2005;28:201–209.
-
Dahlstrom U. Frequent non-cardiac comorbidities in patients with chronic heart failure. Eur J Heart Fail 2005;7:309–316.
-
Braunstein JB, Anderson GF, Gerstenblith G, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 2003;42:1226–1233.
- ↵
Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. Impact of comorbidity on lung cancer survival. Int J Cancer 2003;103:792–802.
- ↵
Rutten FH, Cramer MJ, Lammers JW, Grobbee DE, Hoes AW. Heart failure and chronic obstructive pulmonary disease: an ignored combination?. Eur J Heart Fail 2006;8:706–711.
- ↵
Young RP, Hopkins R, Eaton TE. Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes. Eur Respir J 2007;30:616–622.
- ↵
Hole DJ, Watt GC, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 1996;313:711–715.
- ↵
Sabit R, Bolton CE, Edwards PH, et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:1259–1265.
- ↵
Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol 2007;49:171–180.
- ↵
Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735–2752.
- ↵
Marquis K, Maltais F, Duguay V, et al. The metabolic syndrome in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil 2005;25:226–232.
- ↵
Jørgensen NR, Schwarz P, Holme I, Henriksen BM, Petersen LJ, Backer V. The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease: a cross sectional study. Respir Med 2007;101:177–185.
- ↵
Hjalmarsen A, Aasebo U, Birkeland K, Sager G, Jorde R. Impaired glucose tolerance in patients with chronic hypoxic pulmonary disease. Diabetes Metab 1996;22:37–42.
- ↵
Walker CG, Zariwala MG, Holness MJ, Sugden MC. Diet, obesity and diabetes: a current update. Clin Sci (Lond) 2007;112:93–111.
- ↵
Litonjua AA, Lazarus R, Sparrow D, Demolles D, Weiss ST. Lung function in type 2 diabetes: the Normative Aging Study. Respir Med 2005;99:1583–1590.
- ↵
Ford ES, Mannino DM. Prospective association between lung function and the incidence of diabetes: findings from the National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. Diabetes Care 2004;27:2966–2970.
- ↵
Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932–946.
- ↵
van Eeden SF, Hogg JC. The response of human bone marrow to chronic cigarette smoking. Eur Respir J 2000;15:915–921.
- ↵
Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685–1695.
- ↵
Rahman I, Morrison D, Donaldson K, MacNee W. Systemic oxidative stress in asthma, COPD, and smokers. Am J Respir Crit Care Med 1996;154:1055–1060.
- ↵
Pratico D, Basili S, Vieri M, Cordova C, Violi F, Fitzgerald GA. Chronic obstructive pulmonary disease is associated with an increase in urinary levels of isoprostane F2α-III, an index of oxidant stress. Am J Respir Crit Care Med 1998;158:1709–1714.
- ↵
Repine JE, Bast A, Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am J Respir Crit Care Med 1997;156:341–357.
- ↵
MacNee W, Rahman I. Is oxidative stress central to the pathogenesis of chronic obstructive pulmonary disease?. Trends Mol Med 2001;7:55–62.
- ↵
Sauleda J, Garcia-Palmer FJ, Gonzalez G, Palou A, Agusti AG. The activity of cytochrome oxidase is increased in circulating lymphocytes of patients with chronic obstructive pulmonary disease, asthma, and chronic arthritis. Am J Respir Crit Care Med 2000;161:32–35.
- ↵
Lee SH, Goswami S, Grudo A, et al. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med 2007;13:567–569.
- ↵
Agusti A, MacNee W, Donaldson K, Cosio M. Hypothesis: does COPD have an autoimmune component?. Thorax 2003;58:832–834.
-
Taraseviciene-Stewart L, Scerbavicius R, Choe KH, et al. An animal model of autoimmune emphysema. Am J Respir Crit Care Med 2005;171:734–742.
-
Sullivan AK, Simonian PL, Falta MT, et al. Oligoclonal CD4+ T cells in the lungs of patients with severe emphysema. Am J Respir Crit Care Med 2005;172:590–596.
- ↵
Barnes P, Cosio M. Characterization of T lymphocytes in chronic obstructive pulmonary disease. PLoS Med 2004;1:25–27.
- ↵
Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004;59:574–580.
- ↵
Schols AM, Buurman WA, Staal van den Brekel AJ, Dentener MA, Wouters EF. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 1996;51:819–824.
- ↵
Creutzberg EC, Schols AM, Weling-Scheepers CA, Buurman WA, Wouters EF. Characterization of nonresponse to high caloric oral nutritional therapy in depleted patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:745–752.
- ↵
Rana JS, Mittleman MA, Sheikh J, et al. Chronic obstructive pulmonary disease, asthma, and risk of type 2 diabetes in women. Diabetes Care 2004;27:2478–2484.
- ↵
Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 1999;353:1649–1652.
- ↵
Barzilay JI, Abraham L, Heckbert SR, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 2001;50:2384–2389.
- ↵
Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997;40:1286–1292.
- ↵
Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836–843.
- ↵
Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004;351:2599–2610.
- ↵
McEvoy CE, Ensrud KE, Bender E, et al. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:704–709.
- ↵
Gianni W, Ricci A, Gazzaniga P, et al. Raloxifene modulates interleukin-6 and tumor necrosis factor-α synthesis in vivo: results from a pilot clinical study. J Clin Endocrinol Metab 2004;89:6097–6099.
- ↵
Reid MB, Li YP. Tumor necrosis factor-α and muscle wasting: a cellular perspective. Respir Res 2001;2:269–272.
- ↵
Chambers TJ. Regulation of the differentiation and function of osteoclasts. J Pathol 2000;192:4–13.
- ↵
Jeffery PK. Structural and inflammatory changes in COPD: a comparison with asthma. Thorax 1998;53:129–136.
- ↵
Vernooy JH, Kucukaycan M, Jacobs JA, et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med 2002;166:1218–1224.
- ↵
Agusti AG. Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2:367–370.
- ↵
Kasahara Y, Tuder RM, Taraseviciene-Stewart L, et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest 2000;106:1311–1319.
- ↵
Tuder RM, Zhen L, Cho CY, et al. Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade. Am J Respir Cell Mol Biol 2003;29:88–97.
- ↵
Kasahara Y, Tuder R, Cool C, Lynch D, Flores S, Voelkel N. Endotelial cell death and decreased expression of VEGF and KDR/FLK-1 in smoking-induced emphysema. Am J Respir Crit Care Med 2000;161:A583
- ↵
Takabatake N, Nakamura H, Abe S, et al. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-α system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1179–1184.
- ↵
Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981;1:681–686.
- ↵
Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980;93:391–398.
- ↵
Couillard A, Maltais F, Saey D, et al. Exercise-induced quadriceps oxidative stress and peripheral muscle dysfunction in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167:1664–1669.
- ↵
Koechlin C, Couillard A, Cristol JP, et al. Does systemic inflammation trigger local exercise-induced oxidative stress in COPD?. Eur Respir J 2004;23:538–544.
- ↵
Rabinovich RA, Figueras M, Ardite E, et al. Increased tumour necrosis factor-α plasma levels during moderate-intensity exercise in COPD patients. Eur Respir J 2003;21:789–794.
- ↵
Stewart CE, Newcomb PV, Holly JM. Multifaceted roles of TNF-α in myoblast destruction: a multitude of signal transduction pathways. J Cell Physiol 2004;198:237–247.
- ↵
Oudijk E-JD, Lammers J-WJ, Koenderman L. Systemic inflammation in chronic obstructive pulmonary disease. Eur Respir J 2003;22: Suppl. 46 5s–13s.
- ↵
Barreiro E, de la Puente B, Minguella J, et al. Oxidative stress and respiratory muscle dysfunction in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:1116–1124.
- ↵
Debigare R, Cote CH, Maltais F. Peripheral muscle wasting in chronic obstructive pulmonary disease. Clinical relevance and mechanisms. Am J Respir Crit Care Med 2001;164:1712–1717.
- ↵
Schols AMWJ. Nutritional and metabolic modulation in chronic obstructive pulmonary disease management. Eur Respir J 2003;22: Suppl. 46 81s–86s.
- ↵
Baarends EM, Schols AM, Westerterp KR, Wouters EF. Total daily energy expenditure relative to resting energy expenditure in clinically stable patients with COPD. Thorax 1997;52:780–785.
- ↵
Kotler DP. Cachexia. Ann Intern Med 2000;133:622–634.
- ↵
Morrison WL, Gibson JN, Scrimgeour C, Rennie MJ. Muscle wasting in emphysema. Clin Sci (Lond) 1988;75:415–420.
- ↵
Tisdale MJ. Biology of cachexia. J Natl Cancer Inst 1997;89:1763–1773.
- ↵
Schols AM, Soeters PB, Mostert R, Pluymers RJ, Wouters EF. Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial. Am J Respir Crit Care Med 1995;152:1268–1274.
- ↵
MacNee W, Wiggs B, Belzberg AS, Hogg JC. The effect of cigarette smoking on neutrophil kinetics in human lungs. N Engl J Med 1989;321:924–928.
- ↵
Kasper DL, Braunwald E, Hauser S, Longo D, Jameson JL, Fauci AS, eds. Harrison's Principles of Internal Medicine. 16th Edn. New York, McGraw-Hill, 2007
- ↵
Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115–1140.
- ↵
Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28:88–136.
- ↵
Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome?. Lancet 2007;370:797–799.
- ↵
European Society of Hypertension-European Society of Cardiology Guidelines Committee. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011–1053.
- ↵
Lee JH, Lee DS, Kim EK, et al. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med 2005;172:987–993.
-
Morimoto K, Janssen WJ, Fessler MB, et al. Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease. J Immunol 2006;176:7657–7665.
- ↵
van der Harst P, Voors A, van Gilst W, Bohm M, van Veldhuisen D. Statins in the treatment of chronic heart failure: biological and clinical considerations. Cardiovasc Res 2006;3:e333
- ↵
Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of β-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004;125:2309–2321.
- ↵
Niewoehner DE. The role of systemic corticosteroids in acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Med 2002;1:243–248.
- ↵
Walters JA, Walters EH, Wood-Baker R. Oral corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005;3:CD005374
- ↵
Sin DD, Man SF. Do chronic inhaled steroids alone or in combination with a bronchodilator prolong life in chronic obstructive pulmonary disease patients?. Curr Opin Pulm Med 2007;13:90–97.
- ↵
Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775–789.